AA is an autoimmune disease characterized by hair loss on the scalp, face, and/or body1,2

Approximately 2% of the global population suffer
from AA over the course of their lifetime3,4*

  • AA can affect all ages and typically occurs by age 402,3
  • AA can affect people of various racial and ethnic backgrounds5
  • AA can affect both men and women3,4,6

*Incidence from 1990-2009 in Olmstead County, Minnesota.4

AA is an autoimmune disease
characterized by hair loss on the
scalp, face, and/or body1,2

Approximately 2% of the global population suffer
from AA over the course of their lifetime3,4*

  • AA can affect all ages and typically occurs by age 402,3
  • AA can affect people of various racial and ethnic backgrounds5
  • AA can affect both men and women3,4,6

*Incidence from 1990-2009 in Olmstead County, Minnesota.4

AA produces variable degrees of hair loss.1

Clinical patterns can include2:

AA produces variable degrees of hair loss.1

Clinical patterns can include2:

PATCHY AA:

One, multiple, separate, or conjoined (reticular) patches of hair loss

ALOPECIA
TOTALIS (AT):

Total or near-total hair loss on the scalp

ALOPECIA UNIVERSALIS (AU):

Total to near-total hair loss on all surfaces of the body

AA Disease Progression

While the course of AA is unpredictable, an episode of hair loss lasting >1 year is defined as chronic AA and is an indicator of poor prognosis1,7

Up to 25% of patients with AA are at risk of developing AT or AU8-11

For patients with extensive scalp involvement (>50% hair loss), spontaneous remission rates are low (~8%)12

Additional possible indicators of poor prognosis at the time of initial presentation include onset before age 12, and in particular before age 6, development of multiple discrete patches, extensive hair loss involving >50% of the scalp, ophiasis pattern of alopecia, progression to AT or AU, associated nail disease, associated Trisomy 21, associated atopy, and a positive family history for AA or other organ-specific autoimmune disease.7

References: 1. Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83(1):123-130. 2. Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011. 3. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397-403. 4. Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. J Invest Dermatol. 2014;134(4):1141-1142. 5. Lee H, Jung SJ, Patel AB, Thompson JM, Qureshi A, Cho E. Racial characteristics of alopecia areata in the United States. J Am Acad Dermatol. 2020;83(4):1064-1070. 6. Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006;20(9):1055-1060. 7. Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163-170. 8. MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG; British Association of Dermatologists. Guidelines for the management of alopecia areata. Br J Dermatol. 2003;149(4):692-699. 9. Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichology. 2018;10(2):51-60. 10. Messenger AG, McKillop J, Farrant P, McDonagh AJ, Sladden M. British Association of Dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166(5):916-926. 11. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long-term follow-up study of 191 patients. J Am Acad Dermatol. 2006;55(3):438-441. 12. Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15-24.